-
Caspase-8 Fluorometric Assay Kit Workflow
2026-08-25
Translate IETD-dependent caspase activity into a rapid fluorescence readout for apoptosis, combination-therapy, and programmed cell death research. This workflow also shows how to separate direct Caspase-8 activity measurement from downstream apoptosis or pyroptosis phenotypes.
-
IEM 1460: AMPA Receptor Blocker Workflow
2026-08-24
IEM 1460 enables controlled AMPA receptor inhibition assays for separating fast glutamatergic signaling from downstream excitotoxic injury. This practical guide covers stock preparation, neuronal workflows, electrophysiology, data interpretation, and troubleshooting while distinguishing product-specific evidence from findings reported for the related dual antagonist IEM-1925.
-
1-Phenyl-2-Pentanol and Hepatic Fibrosis
2026-08-24
The reference study identifies 1-phenyl-2-pentanol from Moringa oleifera Lam. leaves as an inhibitor of profibrotic activation in TGF-β1-stimulated human LX-2 hepatic stellate cells. By combining fibrosis-marker analysis, proteomics, and molecular docking, it links the compound’s activity to modulation of TGF-β1 and Wnt/β-catenin signaling while defining important limits for translation beyond cell culture.
-
U-73122: Phospholipase C Inhibitor Workflows
2026-08-23
U-73122 is a practical phospholipase C inhibitor for connecting PLC activity with calcium flux, chemotaxis, and cancer-cell motility. This workflow-focused guide shows how to prepare, dose, and validate the compound while separating pathway-specific effects from cytotoxicity or assay artifacts.
-
High-Throughput Imaging of Fractional Drug Killing
2026-08-22
Inde, Rodencal, and Dixon present a microscopy-based protocol for measuring drug-induced fractional killing as a time-resolved population phenotype rather than relying on a single endpoint. The workflow combines nuclear fluorescent labeling, live/dead imaging, and automated analysis to compare many treatment conditions and reveal variability in MEK1/2 inhibitor responses.
-
Phillygenin and Signaling Pathways in Diabetic Nephropathy
2026-08-21
The reference study identifies phillygenin as a candidate intervention for diabetic nephropathy and connects its protective effects to coordinated suppression of TLR4/MyD88/NF-κB inflammation and restoration of PI3K/AKT/GSK3β signaling. By combining high-glucose podocyte experiments, RNA sequencing, biochemical assays, and db/db mouse studies, the work links reduced inflammatory injury and apoptosis with improved renal function.
-
EMD638683: Practical SGK1 Inhibitor Workflows
2026-08-20
EMD638683 supports mechanism-focused studies that connect SGK1 activity with NDRG1 phosphorylation, actin remodeling, endothelial stiffness, and stress responses. This workflow-oriented guide helps researchers compare pharmacological and genetic evidence while optimizing solubility, dosing, controls, and phenotypic readouts.
-
M344: From Chromatin Biology to Translational Strategy
2026-08-20
M344 is a cell-permeable histone deacetylase inhibitor that connects chromatin remodeling with cancer-cell differentiation, proliferation control, radiation response, and HIV-1 latency research. This thought-leadership guide translates its mechanistic profile into practical experimental design while defining the evidence boundaries between in vitro discovery and clinical translation.
-
Sulfo-NHS-SS-Biotin for Reliable Cell Assays
2026-08-19
Learn how Sulfo-NHS-SS-Biotin (SKU A8005) can complement viability, proliferation, and cytotoxicity assays by enabling controlled, reversible cell-surface protein labeling. This scenario-based guide covers reagent chemistry, assay compatibility, fresh-solution handling, interpretation, and practical vendor selection.
-
Toremifene vs Tamoxifen in Advanced Breast Cancer
2026-08-19
This Cochrane review synthesized randomized evidence comparing toremifene with tamoxifen for advanced breast cancer and found no clear efficacy advantage for either selective estrogen receptor modulator. Its main contribution is a structured comparison of tumor response, disease control, survival, progression, and treatment-related adverse events, while also clarifying the limits of applying older trial evidence to modern oncology workflows.
-
Q-VD(OMe)-OPh for Reliable Apoptosis Assays
2026-08-18
This scenario-driven guide explains how Q-VD(OMe)-OPh (SKU A8165) can improve interpretation of apoptosis, viability, and cytotoxicity experiments. It covers mechanism, assay compatibility, formulation, data analysis, and practical vendor-selection criteria using product information and published colorectal cancer research.
-
Geneticin: From Selection to Translational Insight
2026-08-18
Geneticin and G418 Sulfate are more than routine selection reagents. Their ribosomal mechanism, selection pressure, and exploratory antiviral profile can support better engineered models for studying DNA-repair phenotypes such as MRE11:p.K464R-associated olaparib resistance—provided researchers separate model construction from mechanistic interpretation.
-
SW033291: From Enzyme Kinetics to Tissue Repair
2026-08-17
SW033291 is a mechanistically defined 15-PGDH inhibitor for studying prostaglandin E2 elevation, hematopoiesis stimulation, and tissue repair. This guide connects enzyme potency with cellular and in vivo assay decisions while clarifying what recent muscle-regeneration evidence does—and does not—establish.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Genome Editing
2026-08-17
EZ Cap™ Cas9 mRNA (m1Ψ) is an in vitro transcribed Cas9 transcript engineered as an mRNA with Cap1 structure, a poly(A) tail, and N1-methylpseudouridine. Its design supports mRNA stability and translation efficiency while providing a research-oriented format for CRISPR-Cas9 genome editing in mammalian cells.
-
3-Bromopyruvate Reverses Cetuximab Resistance
2026-08-16
A 2023 Cancer Gene Therapy study shows that combining 3-bromopyruvate with cetuximab can suppress intrinsically and acquired cetuximab-resistant colorectal cancer models. The work links restored FOXO3a activity to coordinated autophagy-dependent ferroptosis and apoptosis, offering a mechanistic framework for studying treatment resistance.